|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYCS |
Gene summary for CYCS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYCS | Gene ID | 54205 |
| Gene name | cytochrome c, somatic | |
| Gene Alias | CYC | |
| Cytomap | 7p15.3 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | G4XXL9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54205 | CYCS | GSM4909277 | Human | Breast | Precancer | 1.17e-04 | 3.29e-01 | 0.0177 |
| 54205 | CYCS | GSM4909282 | Human | Breast | IDC | 8.97e-13 | 4.81e-01 | -0.0288 |
| 54205 | CYCS | GSM4909286 | Human | Breast | IDC | 7.36e-19 | -3.87e-01 | 0.1081 |
| 54205 | CYCS | GSM4909293 | Human | Breast | IDC | 2.35e-05 | -2.32e-01 | 0.1581 |
| 54205 | CYCS | GSM4909294 | Human | Breast | IDC | 2.89e-02 | -1.09e-01 | 0.2022 |
| 54205 | CYCS | GSM4909296 | Human | Breast | IDC | 5.18e-11 | -3.08e-01 | 0.1524 |
| 54205 | CYCS | GSM4909297 | Human | Breast | IDC | 2.50e-20 | -1.02e-01 | 0.1517 |
| 54205 | CYCS | GSM4909298 | Human | Breast | IDC | 3.16e-02 | -8.06e-02 | 0.1551 |
| 54205 | CYCS | GSM4909301 | Human | Breast | IDC | 6.51e-18 | -5.22e-01 | 0.1577 |
| 54205 | CYCS | GSM4909302 | Human | Breast | IDC | 3.95e-03 | -2.75e-01 | 0.1545 |
| 54205 | CYCS | GSM4909308 | Human | Breast | IDC | 2.77e-04 | 3.46e-01 | 0.158 |
| 54205 | CYCS | GSM4909309 | Human | Breast | IDC | 1.39e-02 | -2.52e-01 | 0.0483 |
| 54205 | CYCS | GSM4909311 | Human | Breast | IDC | 3.09e-44 | -6.21e-01 | 0.1534 |
| 54205 | CYCS | GSM4909312 | Human | Breast | IDC | 1.93e-19 | -4.14e-01 | 0.1552 |
| 54205 | CYCS | GSM4909313 | Human | Breast | IDC | 6.09e-14 | -4.21e-01 | 0.0391 |
| 54205 | CYCS | GSM4909316 | Human | Breast | IDC | 5.48e-06 | 2.60e-01 | 0.21 |
| 54205 | CYCS | GSM4909319 | Human | Breast | IDC | 6.03e-54 | -3.72e-01 | 0.1563 |
| 54205 | CYCS | GSM4909320 | Human | Breast | IDC | 6.11e-07 | -3.43e-01 | 0.1575 |
| 54205 | CYCS | GSM4909321 | Human | Breast | IDC | 2.31e-14 | -1.44e-01 | 0.1559 |
| 54205 | CYCS | brca1 | Human | Breast | Precancer | 8.18e-06 | 3.74e-01 | -0.0338 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002290425 | Oral cavity | EOLP | respiratory electron transport chain | 28/2218 | 114/18723 | 1.20e-04 | 1.33e-03 | 28 |
| GO:000906025 | Oral cavity | EOLP | aerobic respiration | 40/2218 | 189/18723 | 1.76e-04 | 1.81e-03 | 40 |
| GO:000612317 | Oral cavity | EOLP | mitochondrial electron transport, cytochrome c to oxygen | 9/2218 | 21/18723 | 3.49e-04 | 3.21e-03 | 9 |
| GO:000612224 | Oral cavity | EOLP | mitochondrial electron transport, ubiquinol to cytochrome c | 6/2218 | 11/18723 | 7.46e-04 | 6.03e-03 | 6 |
| GO:004533325 | Oral cavity | EOLP | cellular respiration | 44/2218 | 230/18723 | 8.67e-04 | 6.75e-03 | 44 |
| GO:002290025 | Oral cavity | EOLP | electron transport chain | 35/2218 | 175/18723 | 1.26e-03 | 9.04e-03 | 35 |
| GO:000609125 | Oral cavity | EOLP | generation of precursor metabolites and energy | 79/2218 | 490/18723 | 2.65e-03 | 1.59e-02 | 79 |
| GO:001598025 | Oral cavity | EOLP | energy derivation by oxidation of organic compounds | 54/2218 | 318/18723 | 4.02e-03 | 2.23e-02 | 54 |
| GO:000691921 | Oral cavity | EOLP | activation of cysteine-type endopeptidase activity involved in apoptotic process | 17/2218 | 78/18723 | 8.89e-03 | 4.12e-02 | 17 |
| GO:004603433 | Oral cavity | NEOLP | ATP metabolic process | 71/2005 | 277/18723 | 1.44e-12 | 3.17e-10 | 71 |
| GO:005254733 | Oral cavity | NEOLP | regulation of peptidase activity | 98/2005 | 461/18723 | 1.77e-11 | 2.56e-09 | 98 |
| GO:004277332 | Oral cavity | NEOLP | ATP synthesis coupled electron transport | 33/2005 | 95/18723 | 3.57e-10 | 3.07e-08 | 33 |
| GO:004277532 | Oral cavity | NEOLP | mitochondrial ATP synthesis coupled electron transport | 33/2005 | 95/18723 | 3.57e-10 | 3.07e-08 | 33 |
| GO:001964632 | Oral cavity | NEOLP | aerobic electron transport chain | 31/2005 | 87/18723 | 5.88e-10 | 4.59e-08 | 31 |
| GO:004586233 | Oral cavity | NEOLP | positive regulation of proteolysis | 80/2005 | 372/18723 | 7.28e-10 | 5.54e-08 | 80 |
| GO:005254833 | Oral cavity | NEOLP | regulation of endopeptidase activity | 88/2005 | 432/18723 | 1.82e-09 | 1.18e-07 | 88 |
| GO:000611932 | Oral cavity | NEOLP | oxidative phosphorylation | 40/2005 | 141/18723 | 4.88e-09 | 2.74e-07 | 40 |
| GO:200011632 | Oral cavity | NEOLP | regulation of cysteine-type endopeptidase activity | 55/2005 | 235/18723 | 1.59e-08 | 7.25e-07 | 55 |
| GO:002290432 | Oral cavity | NEOLP | respiratory electron transport chain | 33/2005 | 114/18723 | 6.20e-08 | 2.42e-06 | 33 |
| GO:004328132 | Oral cavity | NEOLP | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 49/2005 | 209/18723 | 8.94e-08 | 3.36e-06 | 49 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0493216 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
| hsa0513414 | Breast | Precancer | Legionellosis | 19/684 | 57/8465 | 4.62e-08 | 9.12e-07 | 6.98e-07 | 19 |
| hsa0541718 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
| hsa042108 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
| hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0493217 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
| hsa0513415 | Breast | Precancer | Legionellosis | 19/684 | 57/8465 | 4.62e-08 | 9.12e-07 | 6.98e-07 | 19 |
| hsa0541719 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
| hsa0421013 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
| hsa0516317 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYCS | SNV | Missense_Mutation | novel | c.64G>A | p.Glu22Lys | p.E22K | P99999 | protein_coding | deleterious(0.01) | benign(0.162) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| CYCS | SNV | Missense_Mutation | novel | c.163A>G | p.Asn55Asp | p.N55D | P99999 | protein_coding | deleterious(0.05) | benign(0.031) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CYCS | SNV | Missense_Mutation | novel | c.4G>A | p.Gly2Ser | p.G2S | P99999 | protein_coding | deleterious(0.04) | benign(0.167) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CYCS | SNV | Missense_Mutation | novel | c.243G>T | p.Met81Ile | p.M81I | P99999 | protein_coding | tolerated(0.09) | benign(0.167) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYCS | SNV | Missense_Mutation | rs11548796 | c.91N>T | p.Pro31Ser | p.P31S | P99999 | protein_coding | deleterious(0.04) | possibly_damaging(0.786) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CYCS | SNV | Missense_Mutation | novel | c.142T>C | p.Ser48Pro | p.S48P | P99999 | protein_coding | deleterious(0.01) | benign(0.007) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CYCS | SNV | Missense_Mutation | c.281N>C | p.Asp94Ala | p.D94A | P99999 | protein_coding | deleterious(0.01) | benign(0.225) | TCGA-BS-A0TC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CYCS | SNV | Missense_Mutation | c.29N>G | p.Ile10Ser | p.I10S | P99999 | protein_coding | deleterious(0.02) | probably_damaging(0.931) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CYCS | SNV | Missense_Mutation | novel | c.290N>T | p.Ala97Val | p.A97V | P99999 | protein_coding | deleterious(0.03) | benign(0.146) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CYCS | SNV | Missense_Mutation | novel | c.4G>C | p.Gly2Arg | p.G2R | P99999 | protein_coding | deleterious(0.01) | possibly_damaging(0.863) | TCGA-78-7145-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |